China Pharma Holdings (CPHI) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.
- China Pharma Holdings' Income towards Parent Company rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3276.23%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
- Per China Pharma Holdings' latest filing, its Income towards Parent Company stood at -$651482.0 for Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
- China Pharma Holdings' 5-year Income towards Parent Company high stood at -$475976.0 for Q1 2023, and its period low was -$1.4 million during Q2 2024.
- Its 5-year average for Income towards Parent Company is -$902785.3, with a median of -$826669.0 in 2021.
- In the last 5 years, China Pharma Holdings' Income towards Parent Company tumbled by 641855.51% in 2021 and then soared by 6326.01% in 2025.
- Quarter analysis of 5 years shows China Pharma Holdings' Income towards Parent Company stood at -$980719.0 in 2021, then fell by 28.9% to -$1.3 million in 2022, then grew by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then surged by 46.79% to -$651482.0 in 2025.
- Its Income towards Parent Company was -$651482.0 in Q3 2025, compared to -$528367.0 in Q2 2025 and -$785572.0 in Q1 2025.